Showing 151-160 of 181 results for "".
Are We All Clear?
https://practicaldermatology.com/topics/psoriasis/are-we-all-clear/20725/Understanding the safety of biologics for psoriasis in real-world settings.When to Consider Therapeutic Switching in Plaque Psoriasis: Best Practices for Nurse Practitioners, Physician Assistants, and Physicians
https://practicaldermatology.com/topics/psoriasis/when-to-consider-therapeutic-switching-in-plaque-psoriasis-best-practices-for-nurse-practitioners-physician-assistants-and-physicians/21054/What to know about patient experiences and the proper approaches to modifying treatment regimens.New Oral Agent May Shift Psoriasis Treatment Landscape
https://practicaldermatology.com/topics/psoriasis/new-oral-agent-may-shift-psoriasis-treatment-landscape/21258/A notable approval in 2014, apremilast may play an important role in bridging a wide gap in the care of moderate to severe psoriasis.Revisiting Cyclosporine in the Age of Biologics: Update on Efficacy and Mechanism of Action
https://practicaldermatology.com/topics/general-topics/revisiting-cyclosporine-in-the-age-of-biologics-update-on-efficacy-and-mechanism-of-action/21937/Increased understanding of the immunologic basis of psoriasis supports the role of cyclosporine in patient management.Fine Particulate Matter and Eczema
https://practicaldermatology.com/issues/july-2025/fine-particulate-matter-and-eczema/36512/The primary objective of this study was to investigate the potential associations between fine particulate matter (specifically PM2.5) exposure and eczema. Researchers on this study set out to explore whether the odds of having eczema would increase with greater PM2.5 exposure, and to identify whethThe State of Private Equity in 2024: Impact on the Practice of Dermatology
https://practicaldermatology.com/columns/practice-management/state-private-equity-2024-impact-practice-dermatology/27173/Physician Growth Partners recently published a white paper, “State of Dermatology Private Equity,” that evaluated market trends, strategies, and more. Practical Dermatology® spoke exclusively with CEO Michael Kroin about how the evolution of private equity is impacting the everyday practitioner andStirring the Pot: Cannabinoids and Atopic Dermatitis
https://practicaldermatology.com/topics/atopic-dermatitis/stirring-the-pot-cannabinoids-and-atopic-dermatitis/20565/Cannabinoids are a diverse group of compounds that may hold significant therapeutic capabilities applicable to many areas of medicine, including dermatology.Going Beyond Staging for Gene Expression Profiling in Melanoma and Cutaneous Squamous Cell Carcinoma
https://practicaldermatology.com/topics/skin-cancer-photoprotection/going-beyond-staging-for-gene-expression-profiling-in-melanoma-and-cutaneous-squamous-cell-carcinoma/57174/Psoriasis, Biologics, and Cardiovascular Disease: The Heart of the Matter
https://practicaldermatology.com/topics/psoriasis/psoriasis-biologics-and-cardiovascular-disease-the-heart-of-the-matter/23215/A relationship between increased cardiovascular events in patients with psoriasis has implications for management of this chronic disease.A Practical Approach to Home UVB Phototherapy for the Treatment of Generalized Psoriasis
https://practicaldermatology.com/topics/psoriasis/a-practical-approach-to-home-uvb-phototherapy-for-the-treatment-of-generalized-psoriasis/21926/Specialists review the basics of choosing ideal patients for home UVB, delineate key aspects of patient education, and provide detailed information on currently available phototherapy equipment.